Welcome to the DDReg Knowledge Capsule. In this episode, we cut through the industry hype to examine exactly what AI can and cannot do in 2026. Learn why AI struggles with complex, judgment-dependent tasks like clinical risk-benefit assessments, novel product pathway determinations, and health agency negotiations. We map out a practical task classification framework—distinguishing between AI-led, AI-assisted, and strictly human-led operations—to help your team safely leverage technology without compromising compliance.
For more, visit our blog - https://resource.ddregpharma.com/blogs/ai-in-regulatory-affairs/

This Podcast about Nigeria has emerged as one of Africa’s most dynamic pharmaceutical markets, but for global manufacturers, the path to entry is defined by the rigorous oversight of the National Agency for Food and Drug Administration and Control (NAFDAC). In this episode, we move beyond the theory of registration to explore the operational realities of the Nigerian market.We break down the critical stages of the approval process—from pre-submission positioning and utilizing collaborative pathways for WHO-prequalified drugs to navigating the NAPAMS portal and the technicalities of GMP inspections. More importantly, we identify the specific administrative "landmines" that often derail submissions, such as the high-stakes 90-working-day query response deadline, the jurisdictional nuances of notarizing legal documents, and the common pitfalls of Superintendent Pharmacist license renewals.Whether you are an established firm or a new entrant, this session provides the strategic insights needed to avoid administrative delays, ensure import compliance, and achieve a realistic timeline for market access in NigeriaFor Detials - https://resource.ddregpharma.com/blogs/nafdac-drug-registration-nigeria/https://resource.ddregpharma.com/blogs/nafdac-drug-registration-nigeria/

In this episode, we explore why pharmaceutical companies are moving away from traditional internal departments and adopting Regulatory-as-a-Service (RaaS). We break down how this agile model provides on-demand access to global regulatory expertise and advanced technology—such as AI-powered dossiers and autonomous compliance agents—while significantly reducing fixed overhead costs. Tune in to learn how RaaS is helping firms stay "always audit-ready" in a rapidly shifting global landscape

Welcome to the DDReg Knowledge Capsule. In this episode, we demystify the Thailand FDA Priority Review, a process that functions more as a controlled acceleration mechanism than a straightforward fast track. While many sponsors expect a simple path to market, we explore why dossier maturity, therapeutic justification, and submission coherence are the true deciders of speed.
For more details - https://resource.ddregpharma.com/blogs/thailand-fda-priority-review-eligibility-timelines-accelerated-drug-approval-strategy/

This episode explores why Egypt is a top priority for regional expansion, boasting a pharmaceutical sector valued at approximately USD 5.9 billion.We dive into the regulatory framework established by Law No. 151 of 2019, which transitioned authority to the Egyptian Drug Authority (EDA).The discussion covers the essential 10-step authorization process, the mandatory requirement for a locally licensed agent, and the technical intricacies of the Common Technical Document (CTD) dossier
Read View - https://resource.ddregpharma.com/blogs/egypt-eda-drug-approval-regulatory-framework-dossier-requirements-authorization-strategy/

This episode provides a comprehensive guide to the Therapeutic Goods Act 1989, exploring the various pathways for getting prescription medicines onto the Australian Register of Therapeutic Goods (ARTG). We dive into the differences between Standard, Verification, and Priority Review pathways, while highlighting the critical importance of Australian-specific documentation, such as the Australian Specific Annex (ASA) for Risk Management Plans. Listeners will also learn how to avoid common registration pitfalls—including GMP clearance gaps and PI/CMI non-compliance—to ensure a more efficient and successful submission process.
For more, visit our blog: https://resource.ddregpharma.com/blogs/tga-australia-drug-registration/

In this episode of the DDReg Knowledge Capsule, we explore the strategic importance of building a comprehensive, multi-market regulatory approach for rare disease treatments. While orphan drug frameworks in the US, EU, Japan, and Australia share the goal of incentivising development for niche populations, they differ significantly in their prevalence thresholds, eligibility criteria, and financial incentives.
For more details, visit our blog: https://resource.ddregpharma.com/blogs/orphan-drug-designation-strategy/

In this episode, we explore the significant transformation of the medical device landscape in Sri Lanka under the mandate of the NMRA. We break down the risk-based classification system—from low-risk Class One items like bandages to the high-risk apex of Class Three devices like cardiac stents. Learn how international manufacturers can leverage the Global Recognition Pathway to fast-track approvals using existing Five Ten Kay clearances, M D R, or I V D R frameworks. We also dive into essential compliance requirements, including ISO thirteen four eight five quality systems and ISO fourteen nine seven one risk analysis, to help you navigate the 2026 registration process with accuracy and efficiencyFor more, visit our blog - https://resource.ddregpharma.com/blogs/medical-device-registration-in-sri-lanka/

This episode explores the significant 2026 updates to the Ministry of Food and Drug Safety (MFDS) drug registration process in South Korea. We dive into the relaxation of mandatory domestic clinical trials in favour of multinational Phase 3 data, the expansion of the conditional approval pathway for innovative medicines, and the increasing alignment of biosimilar frameworks with international standards. The discussion also covers practical submission strategies using the EZDRUG system and what sponsors should expect regarding review timelines and pharmacovigilance obligations in this evolving market
For more, visit our blog - https://resource.ddregpharma.com/blogs/mfds-drug-registration-in-south-korea/

In this episode of the DDReg Knowledge Capsule, we explore the regulatory complexities of entering the Middle East’s largest pharmaceutical market, currently valued between $10.5 and $12.3 billion. We break down the SFDA’s comprehensive registration process, from the mandatory appointment of a Saudi Authorized Representative (SAR) to the technical nuances of submitting eCTD-compliant dossiers.The discussion highlights critical compliance hurdles, such as the strict requirements for Arabic labeling and the necessity of providing stability data tailored to Zone IVb climatic conditions.We also cover the typical 8 to 18-month approval timeline and the vital post-approval obligations—including pharmacovigilance and five-year renewals—required to maintain market access.This session is designed to help manufacturers transform the registration process from a bureaucratic hurdle into a strategic success